"10.1371_journal.pone.0101904","plos one","2014-07-22T00:00:00Z","Thomas H King; Charles B Kemmler; Zhimin Guo; Derrick Mann; Yingnian Lu; Claire Coeshott; Adam J Gehring; Antonio Bertoletti; Zi Z Ho; William Delaney; Anuj Gaggar; G Mani Subramanian; John G McHutchison; Shikha Shrivastava; Yu-Jin L Lee; Shyamasundaran Kottilil; Donald Bellgrau; Timothy Rodell; David Apelian","GlobeImmune, Inc., Louisville, Colorado, United States of America; Integrated Department of Immunology, University of Colorado School of Medicine, Aurora, Colorado, United States of America; Gilead Sciences Inc., Foster City, California, United States of America; Molecular Microbiology and Immunology & Saint Louis University Liver Center, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America; Agency for Science, Technology and Research (A*STAR), Singapore Institute for Clinical Sciences, Singapore, Singapore; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America","Conceived and designed the experiments: TK CK ZG YL CC A. Gehring AB WD GMS JM SS SK DB TR DA. Performed the experiments: TK CB ZG DM YL A. Gehring ZH SS YLL. Analyzed the data: TK CK ZG DM YL CC A. Gehring AB ZH WD A. Gaggar GMS JM SS YLL SK DB. Contributed reagents/materials/analysis tools: TK WD A. Gehring AB GMS SK TR DA. Wrote the paper: TK WD A. Gehring AB GMS SK TR DA.","W.D., A.G., G.S., and J.M. are employees and shareholders of the commercial company Gilead Sciences, Inc. T.K., C.K., Z.G., D.M., Y.L., C.C., D.B., T.R. and D.A. are or were paid employees of the commercial company GlobeImmune, Inc. at the time this work was performed. Work performed by A.J.G. and A.B. and Z.H. was partially funded by a GlobeImmune-sponsored research agreement. A.B. has funding agreements with Gilead and participates on Gilead advisory boards S.S., Y.L. and S.K. do not have potential competing interests. These facts do not alter the authors adherence to all PLOS ONE policies on sharing data and materials. The restriction is that Gilead Sciences would only share the drug product GS-4774 under specific materials Transfer Agreements because GS-4664 is under active clinical development.","2014","07","Thomas H King","THK",19,TRUE,6,6,7,3,TRUE,TRUE,TRUE,7,"9;12;13;14;16;17;18",TRUE
